Pear Therapeutics locks in $64 mln Series C
Boston and San Francisco-based Pear Therapeutics, a provider of prescription digital therapeutics, has secured $64 million in Series C financing. Temasek led the round with participation from other investors that included Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative, EDBI, Blue Water Life Science Fund LP and Trustbridge Partners.
4 January 2019•1 min read
